Celcuity+Logo.jpg
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
February 28, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
arvinas_logoART_lg.jpg
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024 07:00 ET | Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the...
Celcuity+Logo.jpg
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
February 22, 2024 16:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient...
Picture1.jpg
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
February 22, 2024 06:19 ET | Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
arvinas_logoART_lg.jpg
Arvinas Announces Chief Financial Officer Transition
February 20, 2024 16:05 ET | Arvinas Inc.
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas,...
Celcuity+Logo.jpg
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
February 20, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
arvinas_logoART_lg.jpg
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024 07:00 ET | Arvinas Inc.
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety,...
arvinas_logoART_lg.jpg
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024 06:45 ET | Arvinas Inc.
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK,...
arvinas_logoART_lg.jpg
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Global Oncologists Market
Oncologists Global Market to Reach $27.51 Billion by 2032; Asia-Pacific and North America Lead Growth
January 29, 2024 11:35 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering. The global oncologists...